![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/9/9f/Linagliptin.png/640px-Linagliptin.png&w=640&q=50)
Empagliflozin/linagliptin
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Empagliflozin/linagliptin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.[5][6] It is a combination of empagliflozin and linagliptin.[5][6] It is taken by mouth.[5][6]
Quick Facts Combination of, Linagliptin ...
![]() | |
![]() | |
Combination of | |
---|---|
Empagliflozin | SGLT2 inhibitor |
Linagliptin | DPP-4 inhibitor |
Clinical data | |
Trade names | Glyxambi |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C48H55ClN8O9 |
Molar mass | 923.47 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[5][6]
It was approved for use in the United States in January 2015,[7][8] for use in the European Union in November 2016,[6] and for use in Australia in December 2016.[2]